AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01345370 — intervention group
Intervention type: DRUG
Intervention: Temozolomide
Description: According to sites procedures
Study NCT01345370 — intervention group
Intervention type: RADIATION
Intervention: Radiation Therapy
Description: According to sites procedures
Study NCT01241656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DESI for home viewing
Description: Decision support intervention is a 31 minute DVD mailed to the patients in all of the experimental groups. The program explains the function and location of the prostate and the nature of prostate cancer, including its associated mortality. Next, the program describes the different tests that are used to detect prostate cancer including the digital rectal exam, prostate specific antigen (PSA) test and prostate biopsy.
Study NCT01241656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DESI for viewing at Shared Medical Appointment
Description: Shared medical appointment (SMA) sessions will be led by a mid-level provider. The sessions will begin with an introduction about the importance of making an informed decision about prostate cancer screening. The PSA decision support intervention will be shown and then, after the program, participants will be invited to ask questions or share their thoughts and feelings. At the end of the session, information on how to obtain a PSA screening test will be provided to participants. Men who decide in favor of a PSA test immediately following a SMA will be given a lab order which they can use to have the test performed.
Study NCT01241656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Option of SMA and DESI or DESI only
Description: Shared medical appointment (SMA) sessions will be led by a mid-level provider. The sessions will begin with an introduction about the importance of making an informed decision about prostate cancer screening. The PSA decision support intervention will be shown and then, after the program, participants will be invited to ask questions or share their thoughts and feelings. At the end of the session, information on how to obtain a PSA screening test will be provided to participants. Men who decide in favor of a PSA test immediately following a SMA will be given a lab order which they can use to have the test performed.
Study NCT01998399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
Study NCT01998399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
Study NCT04077164 — intervention group
Intervention type: OTHER
Intervention: No intervention, observational only.
Description: No intervention, this study will use self-report information regarding health, social, and behavioral factors for each member of the couple.
Study NCT04127669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSU 6162
Description: The active ingredient of OSU6162 is the S-enantiomer with the chemical name (S)-3-\[3-(methylsulfonyl)phenyl\]-1-propylpiperidine hydrochloride. The substance is a white powder with a melting point of 177-182°C. Solubility in water is > 2000 mg/ml. Current laboratory code used is OSU6162-HCl. In trial protocol, OSU6162-HCl is shortened to OSU6162.
Study NCT04127669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Circular coated tablet (with identical appearance to active treatment tablets 15 mg).
Study NCT01216722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Strengthening Exercise Program
Description: Home exercise Program. 3-4 days a week. 30 minutes a session. 12 weeks
Study NCT01463020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone delivered BA
Description: A 8 week behavioural activation therapy delivered through smartphone
Study NCT01463020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone delivered mindfulness
Description: A 8 week mindfulness intervention delivered through smartphone
Study NCT04429321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg IV every four weeks, first in combination with capecitabine then alone
Study NCT04429321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: ipilimumab 1/mg/kg IV every 3 weeks x 4 cycles, in combination with Nivolumab
Study NCT04429321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bland embolization
Description: Lipiodol:ethanol embolization of their primary or target tumor
Study NCT03588611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bivalirudin
Description: 0.75mg/kg+ 1.75 mg/kg▪h for the duration of PCI;
Study NCT03588611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: 0.6mg/kg+ 1.75 mg/kg▪h for the duration of PCI;
Study NCT03990259 — intervention group
Intervention type: OTHER
Intervention: Running the CSP Mountain Race
Description: The runners completed a 107,6 km mountain race
Study NCT03205982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wise app with medication adherence reminders
Description: The Intervention group will receive the Wise app that delivers medication adherence reminders.
Study NCT03205982 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Wise app with fitness reminders
Description: The control group will receive the Wise app with fitness reminders
Study NCT01254578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01254578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given orally
Study NCT01254578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03990090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103
Description: Administered SC
Study NCT03990090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT02352103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retzius sparing radical prostatectomy
Description: Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
Study NCT02352103 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vattikuti Urology Institute radical prostatectomy
Description: Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
Study NCT02352103 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: da Vinci Surgical System
Description: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon's capabilities and offer a state-of-the-art minimally invasive option for major surgery.
Study NCT02352103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: da Vinci Surgical System
Description: The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon's capabilities and offer a state-of-the-art minimally invasive option for major surgery.
Study NCT01495923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epidural steroid injection
Description: Injection of steroids and local anesthetic into the epidural space
Study NCT01495923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham epidural steroid injection
Description: Injection of saline into the back muscles
Study NCT01495923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Titration of gabapentin to effect
Study NCT01495923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo gabapentin
Description: Titration of placebo gabapentin
Study NCT02460978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets
Study NCT02460978 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for dapagliflozin
Description: Tablets
Study NCT01261598 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Positron Emission Tomography
Description: Positron Emission Tomography
Study NCT02141217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin/clavulanate
Description: Amoxicillin/clavulanate 1 g bd for at least 5 days or maximum 7 days depending upon the treatment response.
Study NCT02141217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon the treatment response.
Study NCT04254055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: Those subjects included in the experimental group will receive an intervention through a program with plyometric, proprioceptive and strength exercises. The subjects included in the control group will not receive any intervention.
Study NCT04239170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab(SHR-1210)
Description: Camrelizumab(SHR-1210): A humanized monoclonal immunoglobulin
Study NCT01619605 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: shrimp challenge
Description: Patients with history of shrimp allergy and positive skin tests to shrimp were recruited for shrimp challenges After shrimp challenges, patients with anaphylaxis defined as anaphylaxis group, patients with mild reactions defined as mild reaction group, and patients without symptom defined as control group
Study NCT02307318 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SoftSeal Hemostatic Pad
Description: Use of SoftSeal hemostatic device at a transradial access site with a 4 French system with with manual pressure by compression of the ulnar artery.
Study NCT00661570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Provox Vega voice prosthesis (20 Fr)
Description: The current Provox2 voice prosthesis of laryngectomized patients will, when the patient comes in for a change, be replaced with a new, next generation Provox Vega voice prosthesis and insertion system
Study NCT01176188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comfort Care
Description: The intervention will consist of two parts: (1) A 15-20 minute period of parental soothing at the bedside comprised of calming activities which the child and parents are familiar with; (2) A quiet period will follow, in which earmuffs are applied over the child's ears to block auditory stimulation. The intervention will take place twice/24 hours, up to a maximum of 72 hours. Total time of first (daytime) intervention will be 2 hours, and of second (night-time) intervention will be 7 hours.
Study NCT01176188 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual nursing care for the child in the Pediatric Intensive Care Unit, including usual parental involvement and usual exposure to unit noise levels.
Study NCT00655057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-citalopram
Description: Participants will take 10 to 30 mg of s-citalopram daily for 12 weeks.
Study NCT00655057 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Description: Participants will attend twice weekly CBT sessions for 2 weeks and then once weekly sessions for 10 weeks. Sessions will focus on modifying thoughts and behaviors that may contribute to depression.
Study NCT00655057 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TRODAT-1 single photon emission computed tomographic (SPECT) imaging
Description: Participants' striatal dopamine transporter (DAT) levels will be measured using \[99mTc\]TRODAT-1 SPECT with magnetic resonance imaging (MRI) co-localization on two separate occasions. Participants with depression will undergo TRODAT-1 SPECT imaging immediately before and after 12 weeks of their assigned treatment. Healthy participants will undergo TRODAT-1 SPECT imaging at baseline and 12 weeks later.
Study NCT00655057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TRODAT-1 single photon emission computed tomographic (SPECT) imaging
Description: Participants' striatal dopamine transporter (DAT) levels will be measured using \[99mTc\]TRODAT-1 SPECT with magnetic resonance imaging (MRI) co-localization on two separate occasions. Participants with depression will undergo TRODAT-1 SPECT imaging immediately before and after 12 weeks of their assigned treatment. Healthy participants will undergo TRODAT-1 SPECT imaging at baseline and 12 weeks later.
Study NCT01618422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Directly Observed Therapy (DOTS) plus
Description: The regimen used to treat MDR-TB comprises 5 to 6 drugs to which the organism is or likely to be susceptible for the initial 6 months, and then 3 to 4 drugs subsequently. In addition, TB cases with rifampicin resistance but not amounting to MDR-TB are also at risk of unfavourable treatment outcomes. The availability of pretreatment susceptibility test results will provide a guide in selection of drugs in treating such cases.
Study NCT01618422 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Directly Observed Therapy (DOTS)
Description: The DOTS strategy (current strategy) consists of the following measures: political commitment, case detection through bacteriologic evaluation, standardized treatment with supervision and patient support, an effective drug supply system, and a reporting and recording system that allows assessment of treatment. The standard regimen for treatment of new cases of pulmonary TB consists of 6 months treatment, with 4 drugs in the initial phase including isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin, followed by two drugs in the continuation phase including isoniazid and rifampicin. In the treatment of previously treated cases, a standard regimen consisting of 8 months treatment will be used.
Study NCT02186561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pipeline™ Embolization Device/ Pipeline™Flex Embolization Device
Study NCT03983226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Tumor debulking surgery (surgery in recurrent ovarian disease)
Study NCT03983226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin...
Description: Salvage chemotherapy
Study NCT03983226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin...
Description: Salvage chemotherapy
Study NCT03983226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niraparib
Description: Niraparib maintenance therapy
Study NCT03983226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib maintenance therapy
Study NCT02879370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal Inspection and management of low ColoRectal Anastomosis
Description: Low anterior resection with total mesorectal excision (TME), either performed open, laparoscopic or robotic Closure of the rectum with linear or curved stapler with transanal inspection Transanal placement of four 2-0 prolene sutures on the rectal stump, respectively 2 at the extremities of the suture line (left and right) and other two 1 cm medial to each of the previous two sutures Circular stapler is introduced, the 4 tails of the prolene stitches are introduced through the windows (2 in the left and 2 in the right side of the instrument) and gently pulled, to obtain a gradual and homogeneous traction of the tissue and elimination of both previous suture lines and doggy ears, then the stapler is fired The termino-terminal anastomosis is carefully inspected A leak test can be performed (if negative the protective stoma is not performed) An eventual leak can be transanally repaired
Study NCT02312115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Diuretic
Study NCT02312115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT00169910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AUC monitored withdrawal of MMF or CNI
Description: AUC monitored withdrawal of MMF or CNI from a immunosuppressive drug regimen with steroids, CNI and MMF in stable renal transplant recipients
Study NCT03758872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cuff assisted colonoscopy(with cuff use of endocuff vision second generation)
Description: this is a cohort prospective comparative, a group without cuff in 2017, 517 patient included in the retrospective phase, and in 2018, 517 patient will be included in the prospective phase with CUFF for detecting polyps
Study NCT01037972 — intervention group
Intervention type: BEHAVIORAL
Intervention: Conventional physiotherapy
Description: 3 times weekly 30 minutes of conventional physiotherapy to strengthen muscular strength and balance in the lower extremity.
Study NCT01037972 — intervention group
Intervention type: BEHAVIORAL
Intervention: Whole body vibration
Description: 3 times weekly 30 minutes of exercises on a whole body vibration device to strengthen muscular strength and improve muscular balance in the lower extremity.
Study NCT00909818 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard fractionated radiotherapy
Description: standard fractionated radiotherapy 50 Gy/25 fractions
Study NCT00909818 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiotherapy
Description: hypofractionated radiotherapy 40 Gy/15 fractions
Study NCT00656084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 900 mg/m2 on Days 1 and 8 of each 21-day cycle The order of administration will be: Gemzar-->Novantrone-->Rituxan.
Study NCT00656084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone
Description: Novantrone 10 mg/m2on Day 1. The order of administration will be:~Gemzar-->Novantrone-->Rituxan.
Study NCT00656084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Rituxan 375 mg/m2 on Day 1. The order of administration will be:~Gemzar-->Novantrone-->Rituxan.
Study NCT03906175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body hyperthermia
Description: Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization). The hyperthermia will be applied using Heckel-HT3000 MPIIb.
Study NCT03014921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: iron injection
Description: Injection of a 250mL saline solution added with 500mg of iron (Ferinject)
Study NCT03014921 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution injection
Description: Injection of a 250mL saline solution
Study NCT00249795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: oral administration (tablets) once daily
Study NCT00249795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration (tablets) once daily
Study NCT03305406 — intervention group
Intervention type: OTHER
Intervention: Interviews
Description: Interviews will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
Study NCT03536650 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DMR
Description: Procedure: DMR Procedure The Fractyl DMR procedure using the Revita System utilizes an over the wire endoscopic approach to ablate the duodenum. The procedure may be completed in an endoscopic suite or in an operating room depending on the facilities and support at each investigative site. All subjects are monitored and anesthetized by conscious sedation per each facility's standard protocol. A full DMR procedure is defined as 5 complete ablations or 9 axial centimeters of circumferentially ablated tissue in the duodenum. Subjects who do not receive any ablations during the DMR procedure will be followed for safety through the 4 week visit and then discontinued from the study.~Other Names:~DMR Revita
Study NCT02455778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cinnamon
Study NCT01753466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydration
Study NCT04317209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0410
Description: administered intravenously
Study NCT04317209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered intravenously
Study NCT03734406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videoclips
Description: The images contained in the videoclips show the pathophysiological process underlying the two diseases under study, namely deep vein thrombosis and atrial fibrillation.
Study NCT03131674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical physical therapy
Description: Patients receive a multimodal cervical physical therapy treatment
Study NCT04243434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Eligible patients will be randomized in a 1:1 ratio to one of 2 treatment cohorts (Cohorts A or B) to receive either the first cycle of treatment with the VSLI-RTU formulation or the Marqibo formulation and crossover to the other formulation for the second cycle.
Study NCT04243434 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CHOP
Description: CHOP to be administered on Day 1 on Cycle 1 \& 2 ( 21-day Cycle) \& prednisone administration on Days 2 to 5 on Cycle 1 \& 2 ( 21-day Cycle)
Study NCT04243434 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: R-CHOP
Description: R-CHOP to be administered on Day 1 on Cycle 1 \& 2 ( 21-day Cycle) \& prednisone administration on Days 2 to 5 on Cycle 1 \& 2 ( 21-day Cycle)